Central Pharmaceuticals (CENTRALPHL) Stock Overview
Manufactures, markets, and distributes generic human pharmaceutical products in Bangladesh. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CENTRALPHL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Central Pharmaceuticals Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳9.00 |
| 52 Week High | ৳15.90 |
| 52 Week Low | ৳7.10 |
| Beta | 0.43 |
| 1 Month Change | -8.16% |
| 3 Month Change | -10.89% |
| 1 Year Change | -2.17% |
| 3 Year Change | -21.05% |
| 5 Year Change | -32.33% |
| Change since IPO | -54.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| CENTRALPHL | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 5.9% | -1.4% | 0.3% |
| 1Y | -2.2% | -10.3% | -8.7% |
Return vs Industry: CENTRALPHL exceeded the BD Pharmaceuticals industry which returned -10.3% over the past year.
Return vs Market: CENTRALPHL exceeded the BD Market which returned -8.7% over the past year.
Price Volatility
| CENTRALPHL volatility | |
|---|---|
| CENTRALPHL Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in BD Market | 7.9% |
| 10% least volatile stocks in BD Market | 2.7% |
Stable Share Price: CENTRALPHL has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: CENTRALPHL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 76 | Munsur Ahamed | www.centralpharmabd.com |
Central Pharmaceuticals Ltd. manufactures, markets, and distributes generic human pharmaceutical products in Bangladesh. It offers tablets, capsules, liquids, and ointment. The company offers its products in various therapeutic areas, including gastrointestinal, anti-infective vitamins & minerals, allergy cough and cold, analgesic and musculoskeletal, dermatological, anti-diabetic oral rehydration salt, antihistamines, antifungal, vitamins, antihyperglycemic, anti-diabetic, analgesics and antipyretic NSAID; and skin diseases, such as fungal and bacterial infections, eczema, atopic dermatitis, other inflammatory skin diseases requiring corticosteroid therapy, and acne.
Central Pharmaceuticals Ltd. Fundamentals Summary
| CENTRALPHL fundamental statistics | |
|---|---|
| Market cap | ৳1.08b |
| Earnings (TTM) | -৳29.57m |
| Revenue (TTM) | ৳33.51m |
Is CENTRALPHL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CENTRALPHL income statement (TTM) | |
|---|---|
| Revenue | ৳33.51m |
| Cost of Revenue | ৳51.07m |
| Gross Profit | -৳17.56m |
| Other Expenses | ৳12.01m |
| Earnings | -৳29.57m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | -52.42% |
| Net Profit Margin | -88.27% |
| Debt/Equity Ratio | 32.9% |
How did CENTRALPHL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 15:30 |
| End of Day Share Price | 2026/01/01 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Central Pharmaceuticals Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.